Compare Regeneron Pharmaceuticals Inc (REGN) vs Trade Desk Inc (TTD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Trade Desk Inc — how do they compare? Regeneron Pharmaceuticals Inc trades at $807.6 (market cap $83.43B), while Trade Desk Inc trades at $13.9 (market cap $6.59B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 12.7× Trade Desk Inc's market cap, and Regeneron Pharmaceuticals Inc pays a 0.46% dividend while Trade Desk Inc pays none. Which is the better fit depends on your goals.
| REGN | TTD | |
|---|---|---|
Market Cap | $83.43B | $6.59B |
Sector | Health | Technology |
52-Week High | $852.03 | $54.13 |
52-Week Low | $555.51 | $13.03 |
Enterprise Value | $78.14B | $5.54B |
Dividend Yield | 0.46% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $810.31, down 2.1% today, with strong fundamentals including 84.9% gross margins and consistent earnings beats. The stock shows bullish technical signals with support at $805 and resistance at $838, while analyst consensus remains strongly positive with 69% buy ratings. Recent news highlights multiple class action lawsuits related to clinical trial disclosures, creating near-term sentiment headwinds despite solid financial performance.
Outlook remains cautiously optimistic given strong profitability and analyst support, though legal risks and clinical trial uncertainties present challenges. The stock trades above consensus price target of $756.82, suggesting limited near-term upside potential despite robust fundamentals and institutional confidence.
The Trade Desk (TTD) trades at $14.02, down 2.84% amid bearish technical signals and recent earnings misses. The stock faces headwinds from slowing revenue growth (3% in Q2 2026) and a 15% workforce reduction announced in September 2026. Despite solid profitability margins (net margin 13.61%) and reasonable valuation (P/E 16.69), negative cash flow trends and competitive pressures weigh on sentiment. Technical indicators show resistance at $15 with support at $13-14, while analyst consensus remains mixed with a $14.07 price target.
Outlook: TTD's long-term ad-tech positioning and AI innovations (Kokai Zuma) offer growth potential, but near-term execution risks and macro ad demand softness pose challenges. Investors should monitor Q3 earnings and restructuring efficacy for catalysts. Risks include heightened competition and reliance on digital ad spending cycles.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Trade Desk Inc
The Trade Desk Inc is engaged in providing a technology platform for ad buyers. Through its cloud-based platform ad buyers can create, manage, and optimize data-driven digital advertising campaigns across ad formats and channels, including display, video, audio, in-app, native and social, on a multitude of devices. Its products include Data Management Platform, Cross-Device Targeting, Video Advertising, Mobile Advertising, and others.
Read more on TTD →
